Pemetrexed - CJ Healthcare

Drug Profile

Pemetrexed - CJ Healthcare

Latest Information Update: 28 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CJ HealthCare
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mesothelioma; Non-small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Dec 2015 Launched for Mesothelioma in South Korea (IV) prior to December 2015 (CJ Healthcare pipeline, December 2015)
  • 28 Dec 2015 Launched for Non-small cell lung cancer in South Korea (IV) prior to December 2015 (CJ Healthcare pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top